Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
The drug is priced at Rs 2000 for a course of 40 tablets
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
Hitz shall assume new role from January 17th, 2022
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
It is the generic version of molnupiravir
Biogen paid Ionis a US $ 60 million one-time upfront payment
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Subscribe To Our Newsletter & Stay Updated
